Melanoma: all 3,073 studies

Page 27 of 31. Open to participants first (529), then studies with results posted, then the rest; newest registration first within each.

• Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.CompletedNCT00688090Phase 1
• Dendritic Cells (White Blood Cells) Vaccination for Advanced MelanomaCompletedNCT00683670Phase 1
• Patients With Mouse Tyrp2 DNA: A Phase I Trial to Assess Safety and Immune ResponseCompletedNCT00680589Phase 1
• Safety Study of CADI-05 in Patients With Advanced Stage MelanomaTerminatedNCT00675727Phase 1/2
• Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic CellsCompletedNCT00672542Phase 1
• Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery for Stage IB, Stage II, or Stage IIIA MelanomaStatus unknownNCT00672321
• Intratumoral Injection Of Alpha-Gal GlycosphingolipidsCompletedNCT00668512Phase 1
• Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by SurgeryTerminatedNCT00667901Phase 1
• Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid TumorsCompletedNCT00667641Phase 1
• NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or LymphomaCompletedNCT00667082Phase 1
• A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant MelanomaWithdrawnNCT00661336Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Stage IV MelanomaCompletedNCT00658892Phase 1
• CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior TherapyCompletedNCT00658437Phase 2
• Everolimus and Vatalanib in Treating Patients With Advanced Solid TumorsCompletedNCT00655655Phase 1
• Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma PatientsCompletedNCT00651703Phase 2
• Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)CompletedNCT00636558Phase 1
• Clinical Trial of Sutent to Treat Metastatic MelanomaCompletedNCT00631618Phase 2
• In Vitro Expanded Autologous Invariant Natural Killer Cells in CancerCompletedNCT00631072Phase 1
• Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) MalignancyTerminatedNCT00629187Phase 1
• A Study Evaluating the Safety and Antitumor Activity of IPI-504, in Patients With Metastatic MelanomaTerminatedNCT00627419Phase 2
• The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance MelanomaCompletedNCT00626860Phase 1/2
• Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant MelanomaCompletedNCT00625768Phase 1
• Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid TumorsCompletedNCT00625456Phase 1
• Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic MelanomaCompletedNCT00623402Phase 2
• Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the EyeWithdrawnNCT00621439Not applicable
• Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic MelanomaCompletedNCT00617799
• Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced MelanomaCompletedNCT00616564Phase 2
• PTK/ZK in Disseminated Malignant MelanomaTerminatedNCT00615160Phase 1/2
• Differential Risks for Melanoma: p16 and DNA RepairCompletedNCT00615095
• Phase II, 2nd Line Melanoma - RAND MonotherapyCompletedNCT00612664Phase 2
• Phase 1 Study of MPC-6827 and Temozolomide in Metastatic MelanomaCompletedNCT00609011Phase 1/2
• Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting ChemotherapyStatus unknownNCT00604136Phase 2
• ABT-510 in Treating Patients With Metastatic MelanomaCompletedNCT00602199Phase 2
• Effect of rIL-21 on Metastases in Lymph Nodes in Melanoma Skin CancerTerminatedNCT00601861Phase 2
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedNCT00600496Phase 1
• Health Communication in FamiliesCompletedNCT00597961
• A Model for Genetic Susceptibility: MelanomaActive, not recruitingNCT00591500
• Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With MelanomaCompletedNCT00588198
• A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced MelanomaTerminatedNCT00585000Phase 1
• Treatment Use Study for Advanced Melanoma.No longer availableNCT00584493
• Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal TractActive, not recruitingNCT00582647
• Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan BlueCompletedNCT00581698
• Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue SarcomaCompletedNCT00580320Phase 1
• Injection Of AJCC Stage IIB, IIC, III And IV Melanoma Patients With A Multi-Epitope Peptide Vaccine Using GM-CSF DNA As An Adjuvant: A Pilot Trial To Assess Safety And ImmunityCompletedNCT00580060Early Phase 1
• Safety Study of Modified Vaccinia Virus to CancerCompletedNCT00574977Phase 1
• Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic TherapyTerminatedNCT00571116Phase 1
• Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryotherapy in Treating Patients With Stage IV MelanomaCompletedNCT00568763Phase 1
• Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00568048Phase 2
• Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or LegCompletedNCT00565968Phase 1
• Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by SurgeryCompletedNCT00563823Phase 2
• Fotemustine in Treating Patients With Metastatic MelanomaTerminatedNCT00560118Phase 2
• Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma PatientsCompletedNCT00559026Phase 1
• Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver CancerStatus unknownNCT00553683Phase 1/2
• Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma PatientsActive, not recruitingNCT00553618Phase 2
• Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV MelanomaCompletedNCT00553306Phase 1/2
• A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without DacarbazineCompletedNCT00542893Phase 1
• Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque RadiotherapyStatus unknownNCT00540930Phase 4
• Optical Biopsy of Human Skin in Conjunction With Laser TreatmentCompletedNCT00540566
• Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant MelanomaStatus unknownNCT00538005Phase 1/2
• MicroRNA Expression and Function in Cutaneous Malignant MelanomaCompletedNCT00536029
• Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant MelanomaWithdrawnNCT00535314Phase 2
• Taxotere/Temodar/Cisplatin Study in Melanoma PatientsCompletedNCT00527761Phase 1
• Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma PatientsCompletedNCT00527657Phase 1
• A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsCompletedNCT00526617Phase 1
• BI 2536 in Treating Patients With Recurrent or Metastatic Solid TumorsCompletedNCT00526149Phase 2
• Melanoma Detection by Oblique-Incidence Optical SpectroscopyCompletedNCT00526032
• Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in MelanomaTerminatedNCT00522834Phase 3
• Trial of Dacarbazine With or Without Genasense in Advanced MelanomaCompletedNCT00518895Phase 3
• Health Behaviors, Surveillance, Psychosocial Factors, and Family ConcernsCompletedNCT00518050
• A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With DacarbazineCompletedNCT00516802Phase 1
• Vaccination of Melanoma Patients With Dendritic Cells Loaded With Allogeneic Apoptotic-Necrotic Melanoma CellsCompletedNCT00515983Phase 1
• Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant MelanomaCompletedNCT00514085Phase 2
• Adoptive Transfer of MART1/Melan-A CTL for Malignant MelanomaCompletedNCT00512889Phase 1
• Melanoma Risk-Reduction Among Patients and Family MembersCompletedNCT00510302
• Evaluation of a Novel CT-On-Rails or Trilogy Stereotactic Spine Radiotherapy System (SSRS)Active, not recruitingNCT00508443Phase 1/2
• Sample Collection From Melanoma PatientsTerminatedNCT00507325
• Evaluating the Use of Fibrin Tissue Adhesive in Melanoma PatientsCompletedNCT00506311Not applicable
• Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial CancerTerminatedNCT00499733Early Phase 1
• Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other CancersCompletedNCT00498979Phase 1
• Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant MelanomaCompletedNCT00498836Phase 2
• A Phase I/II Study of Sunitinib and DacarbazineTerminatedNCT00496223Phase 1/2
• Prospective Measurement of Post-Treatment LymphedemaCompletedNCT00495950
• Compassionate Use Trial for Unresectable Melanoma With IpilimumabNo longer availableNCT00495066
• Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III MelanomaStatus unknownNCT00492505Phase 2
• Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney CancerTerminatedNCT00492440Phase 1
• Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular MelanomaStatus unknownNCT00489944Phase 2
• A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaCompletedNCT00483301Phase 2
• Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin CellsTerminatedNCT00482105Not applicable
• M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV MelanomaStatus unknownNCT00477906Phase 3
• Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00471471Phase 1
• Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by ElectroporationCompletedNCT00471133Phase 1
• Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by SurgeryCompletedNCT00470379Early Phase 1
• Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, or Stage IV MelanomaCompletedNCT00470015Phase 1
• High-resolution Magnetic Resonance Imaging (MRI) Scans to Look for Spread of Melanoma to Nearby Lymph NodesCompletedNCT00463892Phase 2
• Tilting of Radioactive Plaques After Initial Accurate Placement for Treatment of Uveal MelanomaStatus unknownNCT00459849Not applicable
• Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the SkinCompletedNCT00453050Phase 1
• Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary MelanomaStatus unknownNCT00450593
• High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII MelanomaWithdrawnNCT00447356Phase 3
• Study of Families With MelanomaStatus unknownNCT00445783
• Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular EdemaCompletedNCT00441662Not applicable

← Melanoma overview